Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tivic Health Systems Inc (TIVC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: TIVC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.17% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.68M USD | Price to earnings Ratio - | 1Y Target Price 210 |
Price to earnings Ratio - | 1Y Target Price 210 | ||
Volume (30-day avg) - | Beta 2 | 52 Weeks Range 2.43 - 16.08 | Updated Date 06/29/2025 |
52 Weeks Range 2.43 - 16.08 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2151.43% |
Management Effectiveness
Return on Assets (TTM) -100.63% | Return on Equity (TTM) -218.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1673245 | Price to Sales(TTM) 7.12 |
Enterprise Value 1673245 | Price to Sales(TTM) 7.12 | ||
Enterprise Value to Revenue 3.24 | Enterprise Value to EBITDA 0.16 | Shares Outstanding 965899 | Shares Floating 765790 |
Shares Outstanding 965899 | Shares Floating 765790 | ||
Percent Insiders 12.81 | Percent Institutions - |
Upturn AI SWOT
Tivic Health Systems Inc
Company Overview
History and Background
Tivic Health Systems Inc. was founded in 2016. The company focuses on bioelectronic medicine and wearable neuromodulation devices targeting chronic conditions. Its key milestone includes the FDA clearance and commercialization of ClearUPu00ae.
Core Business Areas
- Neuromodulation Devices: Develops and commercializes non-invasive neuromodulation devices for treating sinus and other inflammatory conditions.
Leadership and Structure
Jennifer Ernst serves as the Chief Executive Officer. The company operates with a management team overseeing areas such as marketing, sales, and research & development. The Board of Directors is the top governing body.
Top Products and Market Share
Key Offerings
- ClearUPu00ae Sinus Relief: ClearUPu00ae is a non-invasive, FDA-cleared device for sinus pain and congestion relief. Market share data is not publicly available. Competitors include traditional decongestants, nasal sprays (OTC and prescription), and alternative therapies like nasal irrigation.
Market Dynamics
Industry Overview
The bioelectronic medicine industry is growing, with increasing interest in non-pharmaceutical approaches to chronic conditions. The market is characterized by innovation and regulatory scrutiny.
Positioning
Tivic Health is positioned as an innovator in the non-invasive neuromodulation space, targeting sinus relief. Its competitive advantage lies in its FDA-cleared device and focus on consumer accessibility.
Total Addressable Market (TAM)
The TAM for sinus relief devices is estimated to be in the billions of dollars, encompassing both OTC and prescription solutions. Tivic is capturing a portion of this with its consumer-focused, non-invasive ClearUP device.
Upturn SWOT Analysis
Strengths
- FDA-cleared product
- Non-invasive solution
- Direct-to-consumer marketing
- Focus on bioelectronic medicine
Weaknesses
- Limited product portfolio
- Relatively small market capitalization
- Negative profit margins
- Dependence on single product success
Opportunities
- Expansion of product line
- Partnerships with healthcare providers
- International market expansion
- Further clinical research to support efficacy
Threats
- Competition from established pharmaceutical companies
- Regulatory changes
- Technological advancements by competitors
- Consumer adoption challenges
Competitors and Market Share
Key Competitors
- JNJ
- SNY
- BAYRY
Competitive Landscape
Tivic Health faces competition from large pharmaceutical companies and other medical device manufacturers. Its advantages lie in its focus on non-invasive neuromodulation, while its disadvantages include smaller scale and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by fluctuating revenues and high expenses.
Future Projections: Future growth is projected based on product sales and partnerships.
Recent Initiatives: Recent initiatives include new marketing campaigns and partnerships to expand reach.
Summary
Tivic Health Systems is a small cap company in a rapidly growing sector with a focus on bioelectronic medicine, but negative profit margins. The company's FDA-cleared product, ClearUPu00ae Sinus Relief, is the company's strength, but it also faces competition from larger pharmaceutical companies. The company requires more effective marketing and partnerships to establish a stronger foothold in the market to ensure future success. Investors must be wary of the negative margins of the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Third Party Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tivic Health Systems Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2021-11-11 | Co-Founder, CEO & Director Ms. Jennifer Ernst | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7 | Website https://tivichealth.com |
Full time employees 7 | Website https://tivichealth.com | ||
Tivic Health Systems, Inc., a health tech company, develops and commercializes bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for use in the treatment of sinus pain, pressure, and congestion. The company sells its products through online retailers and commercial distributors, as well as its own website. Its lead product candidate is Entolimod, a late-stage TLR5 agonist for use in the treatment of acute radiation syndrome. In addition, the company markets its commercial product under the ClearUP Sinus Pain Relief brand name. It also focusses on non-invasive vagus nerve stimulation. The company was incorporated in 2016 and is based in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.